Dexcom (DXCM) EVP has 1,451 shares withheld for RSU tax obligations

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Dexcom executive Michael Jon Brown reported a routine tax-related share withholding tied to restricted stock units. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations from the net settlement of vested RSUs, and the footnote clarifies this was not an open-market sale.

After the withholding, Brown directly holds 108,053 Dexcom shares, which include 74,753 unvested restricted stock units scheduled to vest in tranches through March 8, 2029.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brown Michael Jon

Role EVP Chief Legal Compliance Off

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,451	$71.90	$104K

Holdings After Transaction: Common Stock — 108,053 shares (Direct, null)

Footnotes (1)

Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares withheld for taxes: 1,451 shares Withholding price: $71.90 per share Shares held after transaction: 108,053 shares +4 more

7 metrics

Shares withheld for taxes 1,451 shares Withheld to cover RSU tax obligations

Withholding price <money>$71.90</money> per share Implied value for tax-withholding shares

Shares held after transaction 108,053 shares Direct holdings after tax withholding

Unvested RSUs 74,753 units Included within total reported holdings

2026 RSU grant 39,019 units Granted March 8, 2026; vest through March 8, 2029

2025 RSU grants 28,497 units 19,948 vest through March 8, 2028; 8,549 through March 8, 2027

2024 RSU grant 7,237 units Granted March 8, 2024; vest through March 8, 2027

Key Terms

restricted stock units, net settlement, tax withholding, unvested restricted stock units, +1 more

5 terms

restricted stock units financial

"In connection with the net settlement of restricted stock units and does not represent a sale"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"in connection with the net settlement of restricted stock units and does not represent a sale"

tax withholding financial

"required to be withheld by the Issuer to cover tax withholding and remittance obligations"

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

unvested restricted stock units financial

"Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted"

vest financial

"were granted on March 8, 2026 and shall vest through March 8, 2029"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last)

(First)

(Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Chief Legal Compliance Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/22/2026		F		1,451⁽¹⁾	D	$71.9	108,053⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

2. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Dexcom (DXCM) report for Michael Jon Brown?

Dexcom reported that EVP and Chief Legal Compliance Officer Michael Jon Brown had 1,451 shares of common stock withheld to cover tax obligations from restricted stock units, rather than selling them in the market. This is a standard tax-withholding mechanism disclosed on a Form 4.

Was the Dexcom (DXCM) insider transaction a market sale of shares?

No, the filing states the 1,451 shares represent stock withheld by Dexcom to cover tax withholding and remittance obligations from restricted stock units. The footnote specifically notes this does not represent a sale by Michael Jon Brown into the open market.

How many Dexcom (DXCM) shares does Michael Jon Brown hold after this Form 4?

After the tax-withholding transaction, Michael Jon Brown directly holds 108,053 Dexcom common shares. This total includes both fully vested shares and 74,753 unvested restricted stock units that are scheduled to vest in future periods according to the disclosed vesting schedule.

What restricted stock units (RSUs) position does the Dexcom (DXCM) executive have?

The filing notes that 74,753 of Michael Jon Brown’s reported Dexcom shares are unvested RSUs. These include grants from March 8, 2024, March 8, 2025, and March 8, 2026, with vesting dates running through March 8, 2029, subject to the plan terms.

What does the F transaction code mean in the Dexcom (DXCM) Form 4?

In this Form 4, transaction code F reflects shares withheld to pay taxes or exercise costs. Dexcom’s filing explains the 1,451 shares were retained by the issuer for tax withholding related to RSU settlement, and are not an open-market sale by the reporting person.

How are Michael Jon Brown’s Dexcom (DXCM) RSUs scheduled to vest?

The filing explains that of the 74,753 unvested RSUs, 39,019 were granted on March 8, 2026 and vest through March 8, 2029. Other grants from March 8, 2025 and March 8, 2024 vest through March 8, 2028 and March 8, 2027, respectively.